What are the risks, signs, and management of euglycemic diabetic ketoacidosis in a patient with diabetes taking Jardiance (empagliflozin)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Jardiance and Diabetic Ketoacidosis (DKA)

Jardiance (empagliflozin) carries a serious risk of euglycemic diabetic ketoacidosis (DKA), a life-threatening condition that can occur even when blood glucose levels are below 250 mg/dL, requiring immediate discontinuation of the drug and urgent treatment with insulin, fluids, and carbohydrate replacement. 1

Risk Profile and Mechanism

SGLT2 inhibitors like Jardiance increase susceptibility to DKA through multiple pathways: reduced insulin doses leading to increased ketone production, elevated glucagon levels causing increased lipolysis, and decreased renal clearance of ketones 2. The FDA label explicitly warns that fatal cases have been reported, and the risk is particularly elevated in patients with insulin deficiency 1.

High-Risk Populations and Situations

Before prescribing Jardiance, assess for these predisposing factors 1:

  • Pancreatic insulin deficiency (type 1 diabetes, history of pancreatitis or pancreatic surgery)
  • Acute illness or febrile states
  • Reduced caloric intake or prolonged fasting
  • Insulin dose reduction
  • Alcohol abuse
  • Scheduled surgery (discontinue at least 3 days prior)
  • Post-surgical states

Critical caveat: Jardiance is NOT indicated for type 1 diabetes and significantly increases ketoacidosis risk in this population 1.

Clinical Presentation: The Euglycemic Trap

The most dangerous aspect of SGLT2 inhibitor-associated DKA is its atypical presentation with normal or minimally elevated glucose levels (often <250 mg/dL), which frequently delays diagnosis and treatment 1, 3.

Signs and Symptoms to Recognize

Patients present with severe metabolic acidosis symptoms 1:

  • Nausea and vomiting
  • Abdominal pain
  • Generalized malaise
  • Shortness of breath (labored breathing)
  • Dehydration

Diagnostic Approach

When evaluating any patient on Jardiance with unexplained metabolic acidosis, immediately check 1, 3:

  • Arterial blood gas (pH <7.35)
  • Serum ketones or beta-hydroxybutyrate
  • Urine ketones (often 4+)
  • Anion gap (elevated)
  • Blood glucose (may be normal or <250 mg/dL)

Do not wait for hyperglycemia to diagnose DKA in patients taking SGLT2 inhibitors 1.

Management Algorithm

Immediate Actions When DKA Suspected

  1. Discontinue Jardiance immediately 1
  2. Initiate DKA protocol with insulin infusion, intravenous fluids, and carbohydrate replacement 1, 4
  3. Hospitalize for urgent treatment - this is a life-threatening emergency 1

Treatment Duration and Monitoring

Recent evidence shows that euglycemic DKA can persist or recur for 7-12 days after the last dose of empagliflozin, despite its 12-14 hour half-life 5, 6. Monitor for:

  • Persistent glucosuria and ketonuria (even with normal serum glucose)
  • Recurrent metabolic acidosis up to 2 weeks after discontinuation 5, 6

Do not restart Jardiance until all risk factors for ketoacidosis are completely resolved 1.

Prevention Strategies

Pre-Treatment Assessment

Before initiating Jardiance 1:

  • Screen for insulin deficiency states
  • Evaluate history of pancreatitis or pancreatic surgery
  • Assess dietary patterns (caloric restriction, low-carb diets)
  • Review alcohol use

Perioperative Management

For scheduled surgery 1:

  • Discontinue Jardiance at least 3 days before surgery
  • Hold during critical illness or prolonged fasting
  • Recent case reports demonstrate severe euglycemic DKA occurring post-operatively even when stopped 1 day prior 7, 6

Patient Education (Critical)

Instruct patients to 1:

  • Stop Jardiance immediately if they develop nausea, vomiting, abdominal pain, tiredness, or difficulty breathing
  • Check ketones when possible if symptoms occur
  • Seek emergency medical attention immediately
  • Maintain adequate fluid intake
  • Understand that DKA can occur even with normal blood sugars

Sick-Day Planning

During acute illness 8, 2:

  • Consider temporarily discontinuing Jardiance
  • Monitor for ketoacidosis symptoms
  • Ensure adequate carbohydrate and fluid intake

Special Considerations

The 2025 ADA Guidelines emphasize that while SGLT2 inhibitors provide cardiovascular and renal benefits, clinicians must balance these against DKA risk, particularly in insulin-deficient states 8. The guideline specifically notes that DKA risk mitigation requires sick-day planning and discontinuation before surgery (3-4 days), during critical illness, or prolonged fasting 8.

Common pitfall: Assuming normal glucose rules out DKA in patients on SGLT2 inhibitors. This delayed recognition has led to worse outcomes in multiple reported cases 1, 3.

References

3
Research

Empagliflozin induced euglycemic diabetic ketoacidosis. A case reports.

Annals of medicine and surgery (2012), 2022

Related Questions

How to reduce diabetic ketoacidosis (DKA) risk in patients on Empagliflozin (empagliflozin)?
How do I manage euglycemic diabetic ketoacidosis in a patient on empagliflozin (Jardiance)?
What is the next step in managing a 52-year-old man with empagliflozin (Jardiance)-induced euglycemic DKA who is receiving IV insulin, isotonic saline with potassium supplementation (1.5 g per pint) at 225 mL/h, D5W at 150 mL/h, and has pH 7.30, bicarbonate 18 mmol/L, glucose 10‑11 mmol/L, ketones 3 mmol/L, sodium 135 mmol/L, and potassium 3.9 mmol/L?
Can Jardiance (empagliflozin) cause metabolic acidosis?
What is the most appropriate long-term glucose-lowering therapy for a patient with type 2 diabetes (T2D), on metformin (biguanide) 1g twice daily (BD) and empagliflozin (SGLT2 inhibitor) 25mg daily, following a ketogenic diet, with a history of euglycemic diabetic ketoacidosis (EDKA) and recent episode of gastroenteritis, now with impaired glycemic control (HbA1c 8.7%) and seeking to avoid weight gain?
What is the appropriate work‑up and management for irregular menstrual cycles in a woman of child‑bearing age taking Risperdal (risperidone)?
What medication review considerations and practical tips should be applied to optimize a patient's regimen?
Can scopolamine (hioscina) cause palpitations?
I have a hard 1.5‑inch mass on the left shin that appears like a fat pad externally but feels firm on palpation and has been present for several years; how likely is it to be cancerous?
A patient on levothyroxine 100 µg has thyroid‑stimulating hormone (TSH) 13.5 mIU/L, free thyroxine (free T4) 1.02 ng/dL, and free triiodothyronine (free T3) 2.1 pg/mL; what adjustment to the levothyroxine dose is recommended?
What is the appropriate evaluation and management of paraneoplastic pruritus?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question